Article
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Cancer discovery - 1 Sept 2017
Grommes Christian, Pastore Alessandro, Palaskas Nicolaos, Tang Sarah S, Campos Carl, Schartz Derrek, Codega Paolo, Nichol Donna, Clark Owen, Hsieh Wan-Ying, Rohle Dan, Rosenblum Marc, Viale Agnes, Tabar Viviane S, Brennan Cameron W, Gavrilovic Igor T, Kaley Thomas J, Nolan Craig P, Omuro Antonio, Pentsova Elena, Thomas Alissa A, Tsyvkin Elina, Noy Ariela, Palomba M Lia, Hamlin Paul, Sauter Craig S, Moskowitz Craig H, Wolfe Julia, Dogan Ahmet, Won Minhee, Glass Jon, Peak Scott, Lallana Enrico C, Hatzoglou Vaios, Reiner Anne S, Gutin Philip H, Huse Jason T, Panageas Katherine S, Graeber Thomas G, Schultz Nikolaus, DeAngelis Lisa M, Mellinghoff Ingo K
Abstract excerpt
Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-κB. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown. We performed a phase I clinical trial with ibrutinib, the first-in-class BTK inhibitor, for patients with relapsed or refractory CNS lymphoma. Clinical responses to ibrutinib occurred in 10 of 13 (77%) patients with PCNSL,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.